The US Food and Drug Administration (FDA) has accepted Sobi North America’s avatrombopag (DOPTELET) supplemental new drug ...

The oral BTK inhibitor rilzabrutinib led to rapid and durable platelet responses, reduced bleeding, and improved fatigue in ...

Sanofi has reported that the Phase III LUNA 3 trial of rilzabrutinib for the treatment of persistent or chronic immune ...

Blood disorders are a group of conditions that affect the production, function, or structure of blood cells, leading to ...

The FDA also accepted Sobi’s New Drug Application (NDA) for avatrombopag for oral suspension. Avatrombopag for oral suspension is a capsule where its granules are sprinkled onto a soft food or liquid ...

In the pivotal LUNA 3 study, adult patients with persistent or chronic ITP and severely low platelet counts (median of 15,000/μL) received oral rilzabrutinib 400 mg twice a day (n=133) or placebo ...

The Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) for avatrombopag for the treatment of thrombocytopenia in pediatric patients aged 1 year and older with ...

Sanofi has presented promising results from a phase 3 study of its investigational oral Bruton’s tyrosine kinase (BTK) ...

US says Taiwan president’s routine transit no excuse for China's military pressure ...

Positive results from the pivotal LUNA 3 phase 3 study of rilzabrutinib in adults with persistent or chronic immune thrombocytopenia (ITP), a rare immune-mediated disease, reinforce the efficacy and ...

USA: Findings from the PINES trial suggest that eltrombopag (Promacta) may offer improved outcomes for children with newly ...